Otsuka Reports Two-Year Kidney Function Benefit With Sibeprenlimab in Phase 3 IgA Nephropathy Trial

Sibeprenlimab-szsi (VOYXACT) slowed estimated glomerular filtration rate decline versus placebo over 24 months in adult patients with primary IgA nephropathy, according to Phase 3 VISIONARY results announced by Otsuka. Otsuka…

Continue Reading Otsuka Reports Two-Year Kidney Function Benefit With Sibeprenlimab in Phase 3 IgA Nephropathy Trial

Breaking the Fibrosis Barrier: How Fibrocor Therapeutics Is Revolutionizing Kidney Disease Treatment

Fibrosis, the accumulation of scar tissue in organs, disrupts normal organ function and leads to progressive impairment. Currently, there is no cure, and existing treatments focus primarily on symptom management…

Continue Reading Breaking the Fibrosis Barrier: How Fibrocor Therapeutics Is Revolutionizing Kidney Disease Treatment

GLP-1 Therapies Emerge as Key Tools in CKD Prevention—But Long-Term Success Hinges on Patient Engagement

As reported on Healio, glucagon-like peptide-1 (GLP-1)–based therapies are rapidly reshaping the landscape of diabetes and chronic kidney disease (CKD) management. Originally developed for glycemic control, these agents now play…

Continue Reading GLP-1 Therapies Emerge as Key Tools in CKD Prevention—But Long-Term Success Hinges on Patient Engagement

How Shenqi Dihuang Decoction May Target Key Pathways in IgA Nephropathy: New Mechanistic Insights

Immunoglobulin A nephropathy (IgAN) remains one of the most common primary glomerular diseases worldwide, yet effective treatments are limited. A new study, recently published in Frontiers, offers fresh evidence that…

Continue Reading How Shenqi Dihuang Decoction May Target Key Pathways in IgA Nephropathy: New Mechanistic Insights

The Second Successful Genetically Edited Pig Transplant Performed by Harvard Surgeons at Mass General

Sixty-six-year-old Tim Andrews, a resident of New Hampshire, is the fourth patient worldwide to undergo a pig kidney transplantation. As reported recently in a Mass General News Release, Tim is…

Continue Reading The Second Successful Genetically Edited Pig Transplant Performed by Harvard Surgeons at Mass General
Developing Novel Solutions for ADPKD: An Interview with XORTX Therapeutics’ CEO Dr. Allen Davidoff
Source: Pixabay.com

Developing Novel Solutions for ADPKD: An Interview with XORTX Therapeutics’ CEO Dr. Allen Davidoff

There are limited therapeutic options for people living with autosomal dominant polycystic kidney disease (ADPKD); currently, the only real standards-of-care include dialysis and kidney transplantation. When discussing the therapeutic landscape,…

Continue Reading Developing Novel Solutions for ADPKD: An Interview with XORTX Therapeutics’ CEO Dr. Allen Davidoff

A New Drug to Treat Focal Segmental Glomerulosclerosis and Renewed Hope for Vertex Pharmaceuticals

After several clinical setbacks, Vertex Pharmaceuticals found promising results in its study of a drug to treat a genetic kidney disease called focal segmental glomerulosclerosis (FSGS). As reported recently by…

Continue Reading A New Drug to Treat Focal Segmental Glomerulosclerosis and Renewed Hope for Vertex Pharmaceuticals